Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Hematology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
‘IMROZ’ Study – Clinical Implications
7
Mins
July 2024
Despite what Mohty described as “progressive advances in the field” over recent years, significant unmet needs remain in the front-line…
Read more
12
Mins
24th September 2020
The Impact of Sickle Cell Disease: Updates in Therapeutics, Treatment, Management, and Future Directions
Although VOC are the hallmark of SCD, a lack of VOC events does not prevent chronic multi-organ damage. Patients with sickle cell anaemia (SCA)…
2
Mins
18th September 2020
European LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukaemia: Implications for Ponatinib
Ponatinib is indicated for the treatment of adults with chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib, are intolerant…
9
Mins
17th September 2020
Economic Evaluation of Severe Anaemia
Anaemia is characterised by a decrease in the total amount of red blood cells (RBC) and haemoglobin (Hb) levels, reducing the volume of oxygen transported through the blood…
9
Mins
30th July 2020
Doing More for Patients with Immune Thrombocytopenia: Putting New Recommendations into Practice
The American Society of Hematology (ASH) guidelines and the International Consensus Report (ICR) recommendations were first published in 2010 and 2011…
10
Mins
30th July 2020
Outcomes for Patients with High-Risk Acute Myeloid Leukaemia: Can We Move from Months to Years?
This symposium focussed on the recognition of, and treatment options for, high-risk AML. Prof Cluzeau considered universal or targeted treatment…
2
Mins
30th July 2020
AGILE: Phase III, Double-Blind, Randomised, Placebo-Controlled Study of Ivosidenib in Combination with Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukaemia and an IDH1 Mutation
Isocitrate dehydrogenase 1 (IDH1) is a metabolic enzyme which catalyses the oxidative decarboxylation of isocitrate to α-ketoglutarate…
3
Mins
30th July 2020
Phase Ib/II Study of the IDH1-Mutant Inhibitor Ivosidenib, with the BCL2-Inhibitor Venetoclax +/-Azacitidine in IDH1-Mutated Myeloid Malignancies
Venetoclax is a potent, selective, oral inhibitor of B-cell lymphoma-2. It is approved in the USA in combination with azacitidine, decitabine…
6
Mins
30th July 2020
Pregnancy-Related Thromboembolism in Sickle Cell Disease
Haematological disorders are predominant in the tropical and subtropical countries where major problems of sickle-cell disease (SCD) and thalassaemias…
Loading posts...
« Previous
1
…
6
7
8
9
10
…
21
Next »